When a patient loses 50 pounds on a GLP-1, 12 to 20 of those pounds is lean body mass. For a healthy person that’s fine. For the millions planning to stay on these drugs for years, it’s a clinical problem nobody has solved, and myostatin inhibitors are the engineered response.
That’s the subject of the latest PatentVest Pulse report, “The Muscle Problem,” from PatentVest, @MDB’s IP-intelligence subsidiary. It maps every program in development, every deal, including Lilly’s $1.9 billion acquisition of Versanis, and the IP layer that determines who wins.
Analyzing that layer is PatentVest’s specialty, and the same lens MDB applies to deep-technology companies.
READ FULL REPORT
MDB Capital is a wholly-owned subsidiary of MDB Capital Holdings (Nasdaq: MDBH) and a broker-dealer registered with the U.S. Securities and Exchange Commission, a member of FINRA and a member of SIPC. Securities trading, account management, and investment banking services are offered by MDB Capital. PatentVest, Inc. is a wholly owned subsidiary of MDB Capital Holdings and an affiliated company of MDB Capital.
